Sign inJoin waitlistJoin the waitlist

Marcelo Bonomi

Section Chief, Head and Neck Oncology · Ohio State University Hospital

Credentials: · · · · ·

History

Head and Neck Oncology Section · Ohio State University Hospital
Present

Icahn School of Medicine at Mount Sinai
1993–1995
Internal Medicine
1990–1993
Doctor of Medicine
1986–1990

Research

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial
JAMA Oncology · 2019 · 255 citations
Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer
Chest · 2005 · 139 citations
First BNCT treatment of a skin melanoma in Argentina: dosimetric analysis and clinical outcome
Case report · Applied Radiation and Isotopes · 2004 · 111 citations

Dukagjin Blakaj
36 papers
PB
Priyanka Bhateja
29 papers
James Rocco
25 papers
Sujith Baliga
24 papers · 2 as a fellow
Darrion Mitchell
19 papers
John Grecula
19 papers
Matthew Old
19 papers
Emile Gogineni
16 papers · 1 as a fellow
David Konieczkowski
15 papers
Juan Wisnivesky
15 papers
Sachin Jhawar
14 papers
Ricardo Carrau
12 papers

Clinical trials

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Principal investigator · Active not recruiting · Phase 2
Marcelo Bonomi
2021–2026
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
Principal investigator · Completed · Phase 1
Galera Therapeutics, Inc.
2013–2016
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Site PI · Recruiting
Tempus AI
2024–2028
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Site PI · Recruiting · Phase 2
NRG Oncology
2023–2032